- Home
- UBER vs GKOS Comparison
UBER vs GKOS Comparison
Compare UBER & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBER
- GKOS
- Stock Information
- Founded
- UBER 2009
- GKOS 1998
- Country
- UBER United States
- GKOS United States
- Employees
- UBER N/A
- GKOS N/A
- Industry
- UBER Business Services
- GKOS Medical/Dental Instruments
- Sector
- UBER Consumer Discretionary
- GKOS Health Care
- Exchange
- UBER Nasdaq
- GKOS Nasdaq
- Market Cap
- UBER N/A
- GKOS 5.1B
- IPO Year
- UBER 2019
- GKOS 2015
- Fundamental
- Price
- UBER $75.24
- GKOS $90.26
- Analyst Decision
- UBER Strong Buy
- GKOS Strong Buy
- Analyst Count
- UBER 32
- GKOS 13
- Target Price
- UBER $89.90
- GKOS $155.00
- AVG Volume (30 Days)
- UBER 19.6M
- GKOS 1.0M
- Earning Date
- UBER 05-07-2025
- GKOS 04-30-2025
- Dividend Yield
- UBER N/A
- GKOS N/A
- EPS Growth
- UBER 422.12
- GKOS N/A
- EPS
- UBER 4.56
- GKOS N/A
- Revenue
- UBER $43,978,000,000.00
- GKOS $383,481,000.00
- Revenue This Year
- UBER $16.78
- GKOS $27.84
- Revenue Next Year
- UBER $14.57
- GKOS $27.99
- P/E Ratio
- UBER $16.50
- GKOS N/A
- Revenue Growth
- UBER 17.96
- GKOS 21.85
- 52 Week Low
- UBER $54.84
- GKOS $77.91
- 52 Week High
- UBER $87.00
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- UBER 56.05
- GKOS 41.57
- Support Level
- UBER $72.05
- GKOS $86.16
- Resistance Level
- UBER $73.40
- GKOS $94.55
- Average True Range (ATR)
- UBER 3.73
- GKOS 6.54
- MACD
- UBER 0.55
- GKOS 1.11
- Stochastic Oscillator
- UBER 95.62
- GKOS 54.51
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.